The emergence of new variants, particularly the B 1351 strain from South Africa, poses significant challenges to vaccine effectiveness. While current vaccines from Moderna and Pfizer may still provide some protection, lab data suggests a potential decrease in antibody response against these evolving strains. As the virus continues to mutate, the pharmaceutical industry is adapting its strategies, emphasizing the need for booster shots to maintain efficacy.
